Investigational drug · Phase 2
VX-407
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Autosomal Dominant Polycystic Kidney Disease (ADPKD).
Phase 2Last checked: Nov 19, 2026Latest source record: Sep 21, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
6
Any phase or sponsor naming "VX-407"
First trial start
2025
Nov 19, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "VX-407", any sponsor or status.
Conditions studied
As listed on its trial records.
- Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Approved drugs for the same conditions: Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "VX-407" as an intervention, largest first.
- A Phase 1 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of VX-407 in Healthy ParticipantsPivotal-lookingCompleted
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
NCT06345755 · 159 participants · Start Apr 17, 2024 · Primary completion Jan 27, 2025
Drug: VX-407; Placebo and 2 more · For: Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Sites: Lenexa, Kansas; Montreal, Canada
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
NCT07792408 · 148 participants (planned) · Start Sep 1, 2026 · Primary completion Mar 11, 2027
Drug: VX-407; LNG/EE and 3 more · For: Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Sites: Montreal, Canada
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
NCT07074327 · 74 participants · Start Jul 11, 2025 · Primary completion Feb 20, 2026
Drug: VX-407; LNG/EE and 3 more · For: Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Sites: Overland Park, Kansas
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
NCT07022119 · 32 participants · Start Jun 12, 2025 · Primary completion Feb 24, 2026
Drug: VX-407; Placebo · For: Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Sites: Lenexa, Kansas
- Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW)Active, not recruiting
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
NCT07161037 · 26 participants · Start Nov 19, 2025 · Primary completion Jul 22, 2027
Drug: VX-407 · For: Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Sites: Alabaster, Alabama; Birmingham, Alabama; Los Angeles, California · 43 sites in all
- Absorption, Distribution, Metabolism, and Excretion of 14C-VX-407 After a Single Oral DoseRecruiting
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
NCT07868926 · 8 participants (planned) · Start Oct 16, 2026 · Primary completion Dec 15, 2026
Drug: 14C-VX-407 · For: Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Sites: Lincoln, Nebraska
Newest research
PubMed records naming it or its code names, newest first.
- The Need for Novel Therapeutic Directions in Autosomal Dominant Polycystic Kidney Disease Patient Care.
Cortinovis M, Perico N, Remuzzi G · Clin J Am Soc Nephrol 2026
- Emerging Therapies in Autosomal Dominant Polycystic Kidney Disease.
Chen CY, Hadla M, Khambati I, et al. · Kidney360 2026
- Therapies in autosomal dominant polycystic kidney disease: beyond tolvaptan.
Fang C, Norouzi S, Garimella PS · Curr Opin Nephrol Hypertens 2025
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Vertex Pharmaceuticals.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.